UNSPSC 51162705: Brovanexine

This classification denotes a mucolytic agent with the molecular formula C24H28Br2N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) Y00SD533IW, chemically known as 4-acetoxy-2,4-dibrom-6-((n-cyclohexylmethylamino)methyl)-3-methoxybenzanilid but more generally known as brovanexine, which bears US NIH Compound Identifier 162137. Brovanexine most often comes in base and hydrochloride forms.

UNSPSC 51162705 Brovanexine (Commodity) encompasses pharmaceutical products that state and local governments procure through both direct purchase and cooperative purchasing agreements. Recent solicitations show state and local buyers acquiring naloxone, generic multi-source pharmaceuticals, and over-the-counter products through formal competitive processes. The issuing bodies include county health departments and state-administered cooperative purchasing alliances serving multiple states and local government facilities. Scope of work ranges from small-scale direct procurement of specific drugs (such as naloxone and drug deactivation systems for county community health operations) to large regional contracting for manufacturer supply of generic pharmaceuticals distributed through authorized wholesale networks. Vendors must meet FDA compliance, cGMP certification, and Drug Supply Chain Security Act requirements; maintain appropriate insurance coverage including general liability and professional liability; and comply with standard procurement certifications including E-Verify and drug-free workplace attestation.

Geographic activity centers on Florida and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving participating jurisdictions across multiple states including Oregon. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the county community health building, with a two-year initial term and one-year renewal option; and MMCAP's S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across state and local government facilities, with contract effectiveness July 1, 2026. Both procurements use formal competitive processes (IFB and RFP respectively) and require vendor compliance with federal regulatory standards and detailed product specifications including NDC codes and manufacturing locations.